These biological drugs inhibit either the vascular endothelial growth factor A (VEGF-A) (i.e., bevacizumab), or the epidermal growth factor receptor (EGFR) (i.e., cetuximab and panitumumab), and can be chosen depending on RAS mutation status [4,5] or primary tumor site [6]. This evidence concerns the gene EGFR and neoplasm.